Castle TissueCypher Surpasses 100,000 Orders in Barrett’s
FRIENDSWOOD, Texas, June 16, 2026 Castle Biosciences has announced that its TissueCypher® Barrett’s Esophagus Test has surpassed 100,000 clinical...
Gastroenterology
Advertisement
Takeda’s ENTYVIO Nears Pediatric IBD FDA Approval
OSAKA, Japan and CAMBRIDGE, Massachusetts, June 9, 2026 Takeda has reached a significant regulatory milestone with the U.S. Food...
Abivax’s Obefazimod Delivers Landmark Phase 3 Success in Ulcerative Colitis
PARIS, France, June 1, 2026 Abivax announced positive topline results from its pivotal Phase 3 ABTECT maintenance trial evaluating...
Lilly’s Retevmo Cuts Recurrence Risk by 83% in NSCLC
INDIANAPOLIS, Indiana, May 31, 2026 Eli Lilly and Company has announced groundbreaking results from the pivotal Phase 3 LIBRETTO-432...
Hanmi and Lilly Strike $1.26 Billion Deal for Promising GLP-2 Drug Candidate Sonefpeglutide
SEOUL, South Korea, June 1, 2026 Hanmi Pharm. Co., Ltd. has entered into a landmark global licensing agreement with...
Advertisements
Abivax Reports Strong Three-Year Remission Results for Obefazimod in Ulcerative Colitis
PARIS, France, May 22, 2026 Abivax announced new three-year interim data from Study 108 showing that obefazimod maintained durable...
Takeda Canada Secures REVESTIVE Reimbursement in BC
TORONTO, ON, Canada – May 5, 2026 Takeda Canada Inc. has announced that REVESTIVE® (teduglutide for injection) will now...
Castle Biosciences Unveils TissueCypher Data at DDW 2026
FRIENDSWOOD, TEXAS, May 04, 2026 Castle Biosciences has announced the presentation of new clinical data at Digestive Disease Week...
Apotex Expands U.S. Portfolio via Cumberland Deal
TORONTO, April 23, 2026 Apotex Inc. and Cumberland Pharmaceuticals Inc. announced a strategic transaction to integrate Cumberland’s U.S. branded...
Spyre to Reveal SKYLINE UC Trial Results on April 13
Waltham, Massachusetts | April 10, 2026 Spyre Therapeutics Inc. has announced that it will report topline results from Part...
Advertisement
